Oxford BioDynamics

Oxford BioDynamics is a public precision medicine diagnostics company with a mission to transform clinical decision-making through its proprietary EpiSwitch® technology, which analyzes the 3D architecture of the genome from blood samples. Its key achievements include developing high-accuracy tests for prostate cancer stratification (94% accuracy), checkpoint inhibitor response, and a first-in-class diagnostic for ME/CFS (96% accuracy). The company's strategy is to commercialize these 'clinical smart tests' while leveraging its companion research platform, EpiSwitch Orion, to partner with pharmaceutical companies for drug development and patient stratification.

The EpiSwitch® platform analyzes the three-dimensional architecture of the genome to detect reproducible changes in chromosome conformation associated with disease states and treatment response, using a simple blood sample.

OBD faces competition in oncology from established liquid biopsy (ctDNA) and traditional biomarker companies, but differentiates with its 3D genomic approach. In ME/CFS, it holds a first-mover advantage with peer-reviewed data. Its platform competes with broader epigenetic analysis tools but is specialized in 3D conformation for clinical application.